New test for type of retinitis pigmentosa caused by USH2A gene changes
Part of Eyes & vision clinical trials.
This trial tests a new way to diagnose a specific form of retinitis pigmentosa (an eye disease that causes vision loss) linked to changes in the USH2A gene. The goal is to improve how doctors identify and track this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old
- You have a genetic test confirming your retinitis pigmentosa is caused by USH2A gene mutations
- You can provide your genetic test results to the study team
- You do not have other eye problems like infection, swelling, or wear-and-tear diseases
- You have not had eye surgery in the last 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication (NPI-001) to see if it can preserve the light-sensing cells in the retina for people with retinitis pigmentosa caused by Usher syndrome. It lasts 24 months and requires several eye exams to monitor changes.
This trial tests a drug called NPI-001 (N-acetylcysteine) to see if it can help protect the light-sensing cells in the eyes of people with Usher syndrome, a genetic condition that causes vision and hearing loss. The study lasts 24 months and measures how well the retina stays healthy.
This program tests an experimental gene therapy for adults with retinitis pigmentosa (RP), an inherited eye disease that causes vision loss. It aims to see if the treatment can help preserve or improve vision.
This trial tests a gene therapy injection (UGX202) for people with advanced retinitis pigmentosa (RP) who have very poor vision. It aims to see if the treatment can help improve or preserve sight.
This early study tests a gene therapy designed for people whose vision problems are caused by an RPGR genetic change. It may help slow or improve the eye disease by treating the underlying cause.
This trial tests a new gene therapy called ZVS203e for people with retinitis pigmentosa caused by a specific RHO gene mutation. It aims to see if the treatment is safe and can help improve vision.
Hear when a new USH2A Variant Retinitis Pigmentosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.